# Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment

> **NCT07275216** · PHASE2 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 23 (estimated)

## Conditions studied

- Classic Hodgkin Lymphoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Brentuximab Vedotin
- **PROCEDURE:** Computed Tomography
- **DRUG:** Dacarbazine
- **PROCEDURE:** Echocardiography Test
- **DRUG:** Gemcitabine
- **BIOLOGICAL:** Pembrolizumab
- **OTHER:** Physical Performance Testing
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Pulmonary Function Test

## Key facts

- **NCT ID:** NCT07275216
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2029-10-20
- **Final completion:** 2029-10-20
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07275216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07275216, "Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07275216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*